IMJUDO tremelimumab

Drug Class

CTLA-4 inhibitor monoclonal antibody

Mechanism

Blocks CTLA-4 interaction with CD80/CD86, enhancing T-cell activation, proliferation, and anti-tumor immune response.

Approved Indication

FDA-approved in combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHC).

What This Means For Patients

IMJUDO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2022) — Sources
• EMA — Approved (2023) — Sources

Pivotal Clinical Evidence

• HIMALAYA — Abou-Alfa et al., NEJM Evidence 2022 (NCT03298451) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761298s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo